Background/Aims: Cisplatin-induced acute kidney injury (AKI) involves damage to tubular cells via excess reactive oxygen species (ROS) generation. Stem cell-based therapies have shown great promise in AKI treatment. In this study, we aimed to assess the protective effect and mechanism of bone marrow mesenchymal stem cell (BMSC)-derived conditioned medium (CM) against cisplatin-induced AKI. Methods: In vitro, NRK-52E cells were incubated with cisplatin in the presence or absence of CM, followed by the assessment of cell viability, apoptosis and cell cycle distribution. Then, ICG-001 and IWR-1 were used to inhibit the wnt/β-catenin pathway. Furthermore, intracellular and mitochondrial ROS levels were evaluated using DCFH-DA and MitoSOX, respectively. In vivo, after cisplatin injection, rats were intravenously injected with CM or BMSCs. Sera and kidney tissues were collected on day 3 after cisplatin injection to evaluate changes in renal function and histology. Western blotting and qRT-PCR were employed to determine the expression of wnt/β-catenin pathway-related genes and proteins. Immunohistochemical staining was used to evaluate tubular β-catenin expression in kidney biopsy from AKI patients. Results: CM protected NRK-52E cells from cisplatin-induced injury by restoring the wnt4/β-catenin pathway. In response to ICG-001 and IWR-1, the protective effect of CM was attenuated, characterized by a decrease in cell proliferation and an increase in cell apoptosis and intracellular and mitochondrial ROS levels. Knockdown of β-catenin using siRNAs also suppressed the mitochondrial biogenesis regulators PGC-1α, TFAM and NRF-1. In the rat model, CM significantly alleviated renal function and histology associated with tubular injury and upregulated wnt4 and β-catenin. However, the renoprotective effect of CM was blocked by ICG-001, characterized by exacerbated renal function, suppressed PGC-1α expression and increased mitochondrial ROS. Clinical data showed that the tubular β-catenin
Introduction
Cisplatin is an effective anticancer agent used in the treatment of various solid tumors, including lung, testicular and other cancers. However, toxicity in some organs such as the kidneys limits its use [1] . After being freely filtered through the glomerulus, unbound cisplatin accumulates in renal cells, especially proximal tubular cells. The accumulation of cisplatin leads to nuclear DNA damage, mitochondrial dysfunction, and tubular cell injury, resulting in cell death and causing acute kidney injury (AKI) [2] [3] [4] .
Mesenchymal stem cells (MSCs) have emerged as a promising mode of therapy for AKI [5, 6] . MSCs can modulate inflammation and promote the regeneration of injured cells through the secretion of factors rather than by direct engraftment and differentiation [7] [8] [9] . Cell-free therapy is a promising alternative to the direct infusion of MSCs. Some studies have suggested that conditioned medium (CM) from MSCs is beneficial for the repair of organ injury, such as ischemic heart disease [10] , diabetic endothelial dysfunction [11] , and acute lung injury [12] . However, the effect of CM on cisplatin-induced AKI has not been fully investigated.
Wnt signaling, one of the evolutionarily conserved pathways, is associated with organ development, homeostasis and tissue repair [13] [14] [15] . When wnt ligands bind to Frizzled receptors and LRP5/6 coreceptors, the β-catenin degradation complex is sequestered, leading to the translocation of β-catenin to the nucleus to prompt the expression of target genes regulating cell fate, proliferation and apoptosis [16] [17] [18] [19] . Following AKI, the wnt/β-catenin pathway is involved in the repair of renal tubular cells [20] [21] [22] . Some studies have also suggested that the Wnt signaling pathway can be regulated by MSCs, and this is associated with the repair process after injury [23, 24] .
In this study, we examined the effect of CM on cisplatin-induced kidney injury and further explored the role of the wnt/β-catenin pathway in renoprotection.
Materials and Methods

Bone Marrow MSC (BMSC) Isolation and CM Preparation
Four-week-old Sprague Dawley (SD) rats were anesthetization, sacrificed and then immersed in 75% ethanol. Then, BMSCs were isolated from both lower limb femurs of the rats. BMSCs were cultured in medium with 10% FBS, penicillin and streptomycin.
When BMSCs (passages 5-7) reached 80% confluence, the medium was replaced with serum-free medium for 48 h. Then, the medium was collected and centrifuged at 3000×g for 20 min, and the supernatant was used as CM. For the in vivo experiments, CM was concentrated by centrifugal ultrafilter unit (10K; Millipore) according to the manufacturer's instructions.
Cell Culture and Treatment NRK-52E cells were cultured in DMEM-F12 with 10% FBS. At 80% confluence, the cells were treated as follows: control (no treatment), cisplatin (50 µM cisplatin for 12 h), CM (only CM) and CM+cisplatin (cisplatin treatment with CM).
Cell Viability Assay
The Alamar Blue kit (Invitrogen) was used to determine cell viability according to the manufacturer's protocol. Cells were seeded into 96-well plates. After treatment of cisplatin or CM, 10 µl Alamar Blue solution was added to each well. Then, the plates were incubated at 37°C for 4 h, and the absorbance was measured at 570 nm.
Measurement of Intracellular and Mitochondrial ROS Generation
Intracellular reactive oxygen species (ROS) were measured by flow cytometry with dichloro-dihydrofluorescein diacetate (DCFH-DA; KeyGen Biotech). After treatment, the cells were washed with PBS and incubated with 10 μM DCFH-DA for 20 min at 37°C. The collected cells were analyzed using an Attune NxT Flow Cytometer. For the determination of mitochondrial ROS, cells were treated with 5 μM MitoSOX RED (Thermo Fisher Scientific) for 10 min at 37°C and then examined with a Leica fluorescence microscope.
Western Blotting
Proteins were isolated using lysis buffer. Homogenates were separated via 10% sodium dodecyl-sulfate polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes for antibody probing. After being blocked by 5% non-fat milk for 1 h at room temperature, the membranes were incubated with the primary antibodies (β-catenin, Cell Signaling Technology; wnt4, Santa Cruz Biotechnology; and PGC-1α, Abcam) overnight at 4°C. Following treatment with peroxidase-conjugated secondary antibodies, bands were visualized using enhanced chemiluminescence reagents.
RNA Isolation and Real-Time RT-PCR
Total RNA was isolated using TRI Reagent (Sigma) according to the manufacturer's instructions. Reverse transcription was performed on cDNA using random primers (Takara). SYBR Premix Ex Taq TM (Takara) was used for quantitative real-time PCR. The 18S rRNA gene was used as a housekeeping gene to normalize gene expression.
Rat AKI Model
All experiments were performed on 6-to 8-week-old male SD rats obtained from the Animal Center, Shanghai Medical College, Fudan University. The rats were allowed free access to water and food. All protocols were approved by the Institutional Animal Care and Use Committee of Fudan University.
For the AKI model, SD rats were intraperitoneally injected with 7 mg/kg cisplatin. In the BMSC group, 1 day after cisplatin treatment, the rats were injected with BMSCs via the caudal vein. In the CM group, CM (2 mg) was injected daily into the tail vein of rats. To inhibit β-catenin, ICG-001 was administered intraperitoneally after CM injection. All rats were sacrificed on day 3 post-cisplatin. Each group had 7-8 rats.
Rat Serum Creatinine
Serum creatinine (Scr) levels were determined using the QuantiChrom™ Creatinine Assay Kit (BioAssay Systems, Hayward, CA, USA) according to the manufacturer's instructions.
PAS Staining and Histology Scoring
Kidneys were immersed in 10% neutral formalin and embedded in paraffin. Periodic acid-Schiff (PAS)-stained 4 µm-thick renal sections were histopathologically analyzed in a blinded manner. Ten nonoverlapping fields (200x) of the cortex and outer medulla were randomly selected. Then, injury was scored according to the extent of damage to the tubules (loss of brush border, tubular dilation, cast formation, and cell lysis) as follows: (1) <25% damage; (2) 25-50% damage; (3) 50-75% damage; and (4)>75% damage.
Patient Selection and Renal Immunohistochemistry
We selected 6 patients with AKI (without pre-existing chronic kidney disease (CKD)) according to the criteria of Scr level recommended in KDIGO [25] , and diagnoses of acute tubular necrosis (ATN) were confirmed by renal biopsy. Based on the level of Scr on day 28 after diagnosis, the patients were classified into either the complete recovery or partial recovery group according to the acute dialysis quality initiative (ADQI) [26] . The control group consisted of normal peritumoral tissues obtained from kidney biopsies from patients with renal clear cell carcinoma. The study was approved by the Clinical Research Ethical Committee of Zhongshan Hospital, Fudan University. All patients provided written informed consent. Protein expression analyzed by immunohistochemistry as previously described [27] . Then, positive staining was scored based on the IOD (integrated optical density).
Statistical Analysis
All data are expressed as the mean ± SEM. One-way ANOVA with Tukey's multiple comparison test was used to analyze multiple-groups with a significance cut-off at <0.05. All data were analyzed using GraphPad Prism Software.
Results
CM ameliorated cisplatin-induced injury in NRK-52E cells
Cisplatin induced significant levels of apoptosis in the NRK-52E cells after 12 h of incubation. Compared with that in the cisplatin group, the proportion of apoptotic cells was decreased in the cisplatin+CM group ( Fig. 1(a, b) ). Meanwhile, the relative cell viability in the cisplatin+CM group was restored to 0.79±0.02, which was higher than that in the cisplatin group (0.64±0.03) ( Fig. 1(c) ). Furthermore, the cell cycle distribution analysis indicated that the cisplatin-induced G0/G1 cell cycle arrest was blocked by CM treatment ( Fig. 1(d) ). The proliferation rate of cells ((S+G2/M)/(G0/G1+S+G2/M)) was also upregulated in the cisplatin+CM group than that in the cisplatin group. (Fig. 1(e) ).
CM activated the β-catenin pathway in NRK-52E cells
Given the significant role of β-catenin in kidney development and repair after AKI [15, 20] , we evaluated the expression of β-catenin in tubular cells after CM treatment. In the cisplatin group, the protein expression of β-catenin was significantly lower than that in the control group. However, compared with that in the cisplatin group, the abundance of tubular β-catenin was increased in the cisplatin+CM group ( Fig. 2(a, b) ). Meanwhile, the mRNA levels of Cyclin D1, Myc-1 and Annexin 2, which are downstream targets of β-catenin, were suppressed by cisplatin, and their levels were restored after CM treatment (Fig. 2(c-e) ).
Inhibition of β-catenin reduced the protective effect of CM
To further confirm the role of the Wnt/β-catenin pathway in the protective effect of CM against cisplatin-induced injury, we used two wnt pathway inhibitors ICG-001 and IWR-1: the former antagonizes Wnt/β-catenin/TCF transcription, and the latter inhibits the Wnt/β-catenin pathway by stabilizing the β-catenin degradation complex. The proportion of apoptotic cells was increased with both ICG-001 and IWR-1 relative to that in the cisplatin+CM group ( Fig. 3(a, b) ). The degree of restoration of cell viability in the cisplatin+CM group was also reduced by ICG-001 and IWR-1 (Fig. 3(c) ). Cell proliferation was markedly lower in both the cisplatin+CM+ICG-001 and cisplatin+CM+IWR-1 groups than in the cisplatin+CM group (Fig. 3(d, e) ). Therefore, the CM-induced protection against cisplatin-mediated injury was associated with the activation of the Wnt/β-catenin pathway.
β-catenin was activated by wnt4 in tubular cells
Since CM could induce the Wnt/β-catenin pathway, we attempted to identify the isomer of wnt that mediates β-catenin activation. We investigated the mRNA levels of the wnt family members, including wnt1, wnt2, wnt3a, wnt4, wnt5b, wnt6, wnt7b and wnt10 in NRK-52E cells. Compared to those in the cisplatin group, Wnt4 and wnt10 were downregulated by cisplatin and then restored by CM treatment (Fig. 4(a) ).
Because the level of wnt4 mRNA was much higher than that of wnt10 and because wnt4 has been reported to play a key role in tubulogenesis [28] , we further examined wnt4 Cell 
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Cellular Physiology and Biochemistry treated with CM, excessive ROS levels were reduced ( Fig. 5(a-c) ). In addition, the inhibition of the wnt/β-catenin pathway by ICG-001 abolished the antioxidative effect of CM (Fig. 5(ac) ). The Wnt/β-catenin pathway is also involved in mitochondrial regulation [29] . Therefore, we further determined the expression of PGC-1α, a key regulator of mitochondrial biogenesis, which maintains mitochondrial oxidative balance. After transfection with β-catenin-siRNA or control-siRNA, NRK-52E cells were incubated with cisplatin+CM. As shown in Fig. 6(ac) , PGC-1α protein expression was reduced in the cells transfected with β-catenin-siRNA compared to that in the negative control-transfected cells. In addition, the downstream effectors of PGC-1α, including mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF-1) were also reduced in response to the downregulation of β-catenin via siRNA (Fig. 6(d-e) ).
CM decreased cisplatin-induced kidney injury and activated the wnt/β-catenin pathway in rats
We next use a cisplatin-induced rat kidney injury model to further investigate the role of the wnt/β-catenin pathway in the renoprotective effect of CM. Similar to BMSC treatment, CM administration ameliorated cisplatin-induced injury to rat kidneys, characterized by decreased Scr levels (Fig. 7(c) ) and improved tubular cell morphology (Fig. 7(a-b) ). in the kidney tissues ( Fig. 7(d-f) ) as well as the mRNA levels of Cyclin D1 and Myc-1 ( Fig. 7(gh) ). Therefore, CM exerted a similar effect as that of BMSCs in ameliorating cisplatin-induced kidney injury.
Inhibition of wnt/β-catenin ameliorated the renoprotective effect of CM and increased the production of mitochondrial ROS
To confirm the role of the wnt/β-catenin pathway in the renoprotective effect of CM in vivo, we treated the rats with ICG-001 after CM administration. ICG-001 attenuated the protective effect of CM against cisplatin-induced injury, characterized by augmented impairment of renal function and pathological damage (Fig. 8(a-c) ). Meanwhile, PGC-1α expression was repressed by cisplatin, which was reversed in the cisplatin+CM+DMSO group (Fig. 8(d,e) ). In response to suppression of the wnt/β-catenin pathway by ICG-001, PGC- 
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Cellular Physiology and Biochemistry 1α protein expression was downregulated ( Fig. 8(d,e) ), and mitochondrial ROS levels were also increased ( Fig. 8(f) ). Therefore, the renoprotective effect of CM was associated with the activated wnt/β-catenin pathway, accompanied by a reduction in mitochondrial ROS levels.
Tubular β-catenin expression was associated with the prognosis of patients after AKI
We have demonstrated that the wnt/β-catenin pathway contributes to the renal protection of CM against cisplatin-induced AKI. Therefore, we further determined whether the tubular expression of β-catenin in patients with AKI may be associated with prognosis.
We performed immunohistochemical staining for β-catenin in kidney biopsies of patients diagnosed with AKI (pathological diagnosis as ATN). However, there was no significant difference in the tubular β-catenin levels between samples from patients who experienced complete recovery and the control samples. Meanwhile, the expression of β-catenin was much lower in the patients who experienced partial recovery than in the patients who experienced complete recovery (Fig. 9(a-b) ). However, the Scr levels (estimated at the time of kidney biopsy) of patients in both groups were not significantly different. Therefore, β-catenin expression may be associated with tubular repair after injury.
Discussion
Studies have indicated that MSC therapy can attenuate AKI via the secretion of paracrine factors [9, 30] . It has also been shown that CM treatment in cell-free therapy exerts similar renoprotective effects as those of MSCs [30, 31] . However, the underlying molecular mechanism by which CM protects against AKI is unknown. In the present study, we found that similar to BMSCs, CM attenuated cisplatin-induced kidney injury in rats. Furthermore, the activation of the wnt4/β-catenin pathway in tubular cells by CM ameliorated cell injury by decreasing apoptosis and inhibiting mitochondrial ROS.
The wnt/β-catenin pathway is essential for renal development and is altered after various insults to kidney [32, 33] . After renal ischemia-reperfusion injury (IRI), the wnt/β-catenin pathway is reactivated and induces the repair process after injury [21, 32] . In response to a wnt agonist, renal IRI is mitigated, and regeneration of tubular cells is prompted, characterized by reduced inflammation and oxidative stress [22] . In the clinical samples, β-catenin was expressed in renal tubular cells from both the AKI group Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry and the control groups. However, tubular β-catenin expression was higher in AKI patients who experienced complete recovery at 28 days than in patients who experienced partial recovery. This suggests that tubular β-catenin expression is associated with kidney repair. However, we found that in response to cisplatin-induced injury, β-catenin expression was reduced with an increase in apoptosis and a decrease in proliferation in NRK-52E cells. In the presence of CM, tubular β-catenin expression was restored accompanied with a decreased in cell apoptosis and an increase in cell proliferation. In addition, the downstream effectors of β-catenin, including Myc-1, Cyclin D1 and Annexin 2, were upregulated. Some studies have shown that with the specific depletion of β-catenin in the renal tubule, apoptosis is aggravated in kidneys [20] . When cells were treated with the wnt/β-catenin inhibitors ICG-001 and IWR-1 in vitro, the protective effect of CM was ameliorated. In the rat model, CM attenuated cisplatin-induced injury by restoring β-catenin expression and the mRNA levels of Myc-1 and Cyclin D1. Furthermore, this renoprotective effect was ameliorated by ICG-001. This indicated that β-catenin is activated by CM against cisplatin-induced injury.
Cellular Physiology
As a downstream effector of the canonical wnt pathway, β-catenin can be activated by different wnt isoforms. It has been shown that wnt7b produced by macrophages can promote tubular repair by activating the canonical wnt pathway in the proximal tubular cells [34] . To determine the wnt isoform that was involved in mediating the protective effect of CM, we assessed the mRNA levels of wnt1, wnt2, wnt3a, wnt4, wnt5b, wnt6, wnt7b and wnt10 in NRK-52E cells. In response to cisplatin, only wnt4 and wnt10 levels were restored by CM treatment, with wnt4 being more strongly affected than wnt10. It has been reported that Wnt4 plays a key role in kidney tubulogenesis [28, 35] . In addition, in the early phase of renal IRI, wnt4 is localized near the site of tubule regeneration, and it is involved in the regulation of β-catenin/Cyclin D1 [21] . In our study, CM restored tubular wnt4 protein expression both in vitro and in vivo. Transfection of NRK-52E cells with wnt4-siRNA downregulated β-catenin expression and decreased the mRNA levels of Myc-1 and Cyclin D1. Thus, CM could restore the wnt4/β-catenin pathway in tubules to attenuate cisplatin-mediated injury. 
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Redox imbalance plays a significant role in cisplatin-induced injury to kidneys. The mitochondria are the main energy-producing organelles and the major intracellular source of ROS. During acute cellular injury, excess ROS are released by damaged mitochondria, which augments injury even further [36, 37] . Reduction in ROS by mitochondria-targeted antioxidants can ameliorate cisplatin-induced kidney injury [37] . In our study, intracellular and mitochondrial ROS were elevated in NRK-52E cells after incubation with cisplatin. Moreover, when the cells were treated with CM, the intracellular and mitochondrial ROS were reduced. Several studies in the literature have reported that the depletion of β-catenin aggravates oxidative stress [38, 39] . We also found that the inhibition of the wnt/β-catenin pathway in NRK-52E cells by ICG-001 negated the CM-mediated suppression of excessive ROS. This was also confirmed in our rat model, indicating that mitochondrial ROS were involved in the wnt/β-catenin pathways regulated by CM.
PGC-1α, a transcriptional coactivator, can interact with NRF-1 and regulate TFAM to prompt mitochondrial biogenesis and maintain mitochondrial redox balance [40] . Therefore, the activation or overexpression of PGC-1α can attenuate AKI and prompt the renal recovery [41, 42] . Recently, some studies have shown that the wnt pathway regulates mitochondrial function [29, 43] . The overexpression of wnt1 in the hepatocytes of mice demonstrated an overall decrease in ROS levels accompanied with the nuclear accumulation of PGC-1α and p-Sirt1 [44] . In our study, when β-catenin was depleted in NRK-52E cells via siRNAs, PGC-1α, TAFM and NRF-1 were inhibited. In the rat model, CM restored PGC-1α expression, which has been suppressed by cisplatin. Similarly, inhibition of the wnt/β-catenin pathway downregulated PGC-1α. Therefore, the wnt/β-catenin pathway regulates mitochondrial ROS via PGC-1α.
Conclusion
We uncovered the underlying molecular mechanism associated with the renoprotective effect CM against cisplatin-induced injury and found it to be mediated by the activation of the wnt/β-catenin pathway, the suppression of excessive cellular ROS and the reduction in tubular apoptosis. However, additional clinical studies are necessary to confirm the effect of CM as a potential therapeutic agent for AKI patients.
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